Rockwell Medical Sales Plummet, Swings to Loss Amid Macro Headwinds

TL;DR

**RMTI's bleeding cash and sales are tanking; management's 'sufficient funds' claim feels like a band-aid on a gaping wound – stay away.**

AI Summary

Rockwell Medical, Inc. (RMTI) reported a significant decline in financial performance for the three and six months ended June 30, 2025. Net sales decreased by 37.8% to $16.07 million for the three months ended June 30, 2025, from $25.83 million in the prior year, and by 27.8% to $34.98 million for the six months ended June 30, 2025, from $48.51 million in 2024. This led to a net loss of $1.49 million for the quarter, a sharp reversal from a net income of $0.34 million in the same period last year. The six-month net loss widened to $3.01 million from $1.39 million. Gross profit also fell substantially, from $4.55 million to $2.50 million for the quarter. The company utilized $1.64 million in cash from operating activities for the six months ended June 30, 2025, compared to $0.94 million in 2024. Despite these losses, management believes it has sufficient funds for the next twelve months, with $18.4 million in cash, cash equivalents, and available-for-sale investments, and $20.7 million in net working capital as of June 30, 2025. The company is actively pursuing new customers and implementing cost containment, while also evaluating the impact of the recently enacted U.S. federal statute P.L. 119-21.

Why It Matters

Rockwell Medical's substantial revenue decline and shift to a net loss signal significant operational challenges that could impact investor confidence and future growth prospects. The company's reliance on its ATM facility for potential capital raises, alongside a competitive landscape in hemodialysis products, puts pressure on its ability to innovate and expand. For employees, continued financial underperformance could lead to restructuring or job insecurity. Customers might face concerns about the long-term stability of a key supplier, potentially seeking alternatives. The broader market for medical device and healthcare suppliers will watch how RMTI navigates these headwinds, especially given the uncertain global macroeconomic environment and recent legislative changes like P.L. 119-21.

Risk Assessment

Risk Level: high — Rockwell Medical reported a net loss of $1.49 million for the quarter and $3.01 million for the six months ended June 30, 2025, a significant deterioration from prior periods. Net sales decreased by 37.8% quarter-over-quarter, indicating substantial business contraction. The company also used $1.64 million in cash from operating activities in the first half of 2025, highlighting ongoing cash burn despite management's liquidity claims.

Analyst Insight

Investors should exercise extreme caution and consider divesting RMTI shares given the sharp decline in sales, widening losses, and ongoing cash burn. Monitor the company's ability to secure new customers and the effectiveness of cost containment measures, as well as any further capital raises through its ATM facility, before considering any new positions.

Financial Highlights

debt To Equity

0.73

revenue

$34.98M

operating Margin

-7.74%

total Assets

$52.625M

total Debt

$22.216M

net Income

-$3.01M

eps

N/A

gross Margin

15.85%

cash Position

$18.4M

revenue Growth

-27.8%

Key Numbers

• $16.07M — Net Sales (Q2 2025) (Decreased by 37.8% from $25.83M in Q2 2024)
• $34.98M — Net Sales (H1 2025) (Decreased by 27.8% from $48.51M in H1 2024)
• $(1.49M) — Net Loss (Q2 2025) (Shifted from a net income of $0.34M in Q2 2024)
• $(3.01M) — Net Loss (H1 2025) (Widened from a net loss of $1.39M in H1 2024)
• $(1.64M) — Net Cash Used in Operating Activities (H1 2025) (Increased from $(0.94M) in H1 2024)
• $18.4M — Cash, Cash Equivalents and Investments Available-for-Sale (Total liquidity as of June 30, 2025)
• $20.7M — Net Working Capital (As of June 30, 2025)
• 34,430,352 — Common Stock Shares Outstanding (As of August 6, 2025)
• $21.1M — Available under ATM facility (Potential source of additional capital)
• 37.8% — Q2 Net Sales Decrease (Percentage decrease in net sales for the three months ended June 30, 2025, compared to the same period in 2024)

Key Players & Entities

• ROCKWELL MEDICAL, INC. (company) — Registrant and healthcare company
• Innovatus Life Sciences Lending Fund I, LP (company) — Lender with whom Rockwell Medical has a Loan Agreement
• U.S. Securities and Exchange Commission (regulator) — Governing body for financial filings
• Nasdaq Capital Market (market) — Exchange where RMTI Common Stock is registered
• Rockwell Transportation, Inc. (company) — Wholly-owned subsidiary of Rockwell Medical
• Rockwell Medical India Private Limited (company) — Wholly-owned subsidiary of Rockwell Medical
• P.L. 119-21 (law) — U.S. federal statute enacted July 4, 2025, affecting tax and spending policies
• Michigan (location) — State of incorporation in 1996 and location of headquarters
• Delaware (location) — State of re-domiciliation in 2019
• Wixom (location) — City where Rockwell Medical's headquarters is located

FAQ

Risk Factors

• Impact of New Federal Statute [medium — regulatory]: The company is evaluating the impact of the recently enacted U.S. federal statute P.L. 119-21. The specific nature of this impact is not detailed, but it is a factor management is considering, suggesting potential operational or financial adjustments may be required.
• Declining Sales and Widening Losses [high — financial]: Net sales decreased by 37.8% to $16.07 million in Q2 2025 and by 27.8% to $34.98 million in H1 2025. This led to a net loss of $1.49 million in Q2 2025, a reversal from a $0.34 million profit, and a widened net loss of $3.01 million in H1 2025 from $1.39 million.
• Increased Cash Burn from Operations [medium — financial]: The company utilized $1.64 million in cash from operating activities for H1 2025, an increase from $0.94 million in H1 2024. This indicates a worsening operational cash flow despite management's belief in sufficient liquidity.
• Dependence on Customer Acquisition [medium — operational]: The company is actively pursuing new customers to counteract declining sales. The success of these efforts is critical for future revenue generation and financial stability.
• Inventory Reduction [low — financial]: Inventory decreased from $5,778,000 at December 31, 2024, to $4,160,000 at June 30, 2025. While this can improve cash flow, a significant reduction might also indicate lower production or sales expectations.

Industry Context

Rockwell Medical operates in the healthcare sector, specifically focusing on products for the treatment of kidney disease. The industry is characterized by stringent regulatory oversight, evolving treatment protocols, and competition from both large established players and smaller innovative companies. Reimbursement policies from government and private payers significantly influence market dynamics.

Regulatory Implications

The recent enactment of U.S. federal statute P.L. 119-21 presents an unknown regulatory risk. Management is evaluating its impact, which could affect product sales, operational costs, or compliance requirements. Further details on the statute's provisions are needed to assess the full scope of its implications.

What Investors Should Do

1. Monitor customer acquisition progress
2. Scrutinize the impact of P.L. 119-21
3. Analyze cash burn rate and liquidity runway

Key Dates

• 2025-06-30: End of Q2 and H1 reporting period — Financial results for the period show significant sales decline and increased net losses, impacting investor sentiment.
• 2025-08-06: Common Stock Shares Outstanding reported — Provides an update on the company's share count, relevant for per-share calculations and market capitalization.

Glossary

Investments Available-for-Sale

Securities that are bought with the intention of selling them in the short term, but not for immediate resale. They are reported at fair value on the balance sheet. (Represents a portion of the company's liquid assets, contributing to its overall cash position of $18.4 million.)

Net Working Capital

The difference between a company's current assets and current liabilities. It is a measure of both its operational efficiency and its short-term financial health. (The company reported $20.7 million in net working capital, indicating its ability to meet short-term obligations.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a negative balance in retained earnings. (The company has an accumulated deficit of $400.685 million as of June 30, 2025, reflecting its history of net losses.)

ATM facility

At-the-Market facility, a type of equity offering where a company sells shares of its stock on a stock exchange at the prevailing market prices. (The company has $21.1 million available under its ATM facility, representing a potential source of additional capital.)

Year-Over-Year Comparison

Compared to the prior year, Rockwell Medical has experienced a significant downturn. Net sales for Q2 2025 dropped by 37.8% and for H1 2025 by 27.8%. This revenue decline has reversed profitability, leading to net losses in both periods, whereas last year saw net income in Q2 and a smaller net loss in H1. Operating cash flow has also deteriorated, with cash used increasing from $0.94 million to $1.64 million in H1. Gross profit margins have compressed, reflecting higher cost of sales relative to revenue.

Key Financial Figures

• $0.0001 — ch registered: Common Stock, par value $0.0001 RMTI Nasdaq Capital Market The number

Filing Documents

• rmti-20250630.htm (10-Q) — 1085KB
• rmti-20250630x10qex101eip.htm (EX-10.1) — 164KB
• rmti-20250630xex102psuagmt.htm (EX-10.2) — 29KB
• rmti-20250630x10qex311.htm (EX-31.1) — 9KB
• rmti-20250630x10qex312.htm (EX-31.2) — 9KB
• rmti-20250630x10qex321.htm (EX-32.1) — 4KB
• rmti-20250630x10qex322.htm (EX-32.2) — 4KB
• 0001041024-25-000011.txt ( ) — 7845KB
• rmti-20250630.xsd (EX-101.SCH) — 53KB
• rmti-20250630_cal.xml (EX-101.CAL) — 87KB
• rmti-20250630_def.xml (EX-101.DEF) — 287KB
• rmti-20250630_lab.xml (EX-101.LAB) — 711KB
• rmti-20250630_pre.xml (EX-101.PRE) — 518KB
• rmti-20250630_htm.xml (XML) — 1113KB

— Financial Information (unaudited)

Part I — Financial Information (unaudited)

- Unaudited Financial Statements

Item 1 - Unaudited Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 9

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 17

- Quantitative and Qualitative Disclosures about Market Risk

Item 3 - Quantitative and Qualitative Disclosures about Market Risk 21

- Controls and Procedures

Item 4 - Controls and Procedures 21

— Other Information

Part II — Other Information

- Legal Proceedings

Item 1 - Legal Proceedings 21

- Risk Factors

Item 1A - Risk Factors 22

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 22

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 22

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 22

- Other Information

Item 5 - Other Information 22

- Exhibits

Item 6 - Exhibits 22

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ROCKWELL MEDICAL, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and par value amounts) June 30, 2025 December 31, 2024 ASSETS Cash and Cash Equivalents $ 12,482 $ 15,662 Investments Available-for-Sale 5,940 5,940 Accounts Receivable, net 8,084 8,291 Inventory, net 4,160 5,778 Prepaid and Other Current Assets 943 1,359 Total Current Assets 31,609 37,030 Property and Equipment, net 5,129 5,785 Inventory, Non-Current — 178 Right of Use Assets - Operating, net 3,408 3,215 Right of Use Assets - Financing, net 1,066 1,344 Intangible Assets, net 9,931 10,207 Goodwill 921 921 Other Non-Current Assets 561 528 Total Assets $ 52,625 $ 59,208 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable $ 1,502 $ 2,869 Accrued Liabilities 4,096 6,275 Deferred Consideration - Current 2,500 2,371 Lease Liabilities - Operating - Current 1,455 1,566 Lease Liabilities - Financing - Current 622 599 Deferred License Revenue - Current — 46 Insurance Financing Note Payable 660 268 Customer Deposits 111 97 Total Current Liabilities 10,946 14,091 Lease Liabilities - Operating - Long-Term 2,008 1,699 Lease Liabilities - Financing - Long-Term 614 931 Term Loan - Long-Term, net of Issuance Costs 8,648 8,472 Deferred License Revenue - Long-Term — 429 Deferred Consideration - Long-Term — 1,000 Total Liabilities 22,216 26,622 Commitments and Contingencies (see Note 13) 3 June 30, 2025 December 31, 2024 Stockholders' Equity: Preferred Stock, $ 0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common Stock, $ 0.0001 par value; 170,000,000 shares authorized; 34,430,352 and 34,056,920 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 3 3 Additional Paid-in Capital 431,034 430,207 Accumulated Deficit ( 400,685 ) ( 397,678 ) Accumulated Other Comprehensive Income 5

View Full Filing

View this 10-Q filing on SEC EDGAR